Programmed cellular immunotherapeutic - Fate Therapeutics

Drug Profile

Programmed cellular immunotherapeutic - Fate Therapeutics

Alternative Names: FT1050/FT4145 - modulated mobilised peripheral blood; Programmed mobilised peripheral blood; ProTmune; ProTmune FT1050/FT4145 programmed mobilised peripheral blood

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator The Scripps Research Institute
  • Developer Fate Therapeutics
  • Class Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cytomegalovirus infections; Graft-versus-host disease

Most Recent Events

  • 07 Oct 2016 Fate Theraeputics receives patent allowance for Programmed cellular immunotherapeutic in USA
  • 01 Oct 2016 Programmed cellular immunotherapeutic - Fate Therapeutics receives Orphan Drug status for Graft-versus-host disease (Prevention) in Europe
  • 26 Sep 2016 Programmed cellular immunotherapeutic - Fate Therapeutics receives Orphan Drug status for Graft-versus-host disease (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top